BOSTON, Jan. 15, 2014 /PRNewswire/ -- Tegra Medical is very pleased to announce the appointment of Mr. J. Mark King as its new Chief Executive Officer. Mark was promoted from his current role of Chief Operating Officer, in which he has overseen the company's four facilities in Massachusetts, Mississippi, and Costa Rica. Mr. King joined Tegra Medical in 2012 with 20+ years of broad-based operations, sales, engineering and manufacturing experience in medical device businesses, both in branded product lines and in contract manufacturing. Prior to joining Tegra, Mark was President and CEO of Clinical Innovations, a market leader in women's health medical devices. During his career, he has held leadership positions with several other related companies, including Baxter Healthcare, Cardinal Health and Johnson and Johnson. Mark is a Six Sigma Green Belt.
"I am eager to continue the operational progress we have achieved at Tegra so that we can serve our customers well," said King. "Tegra Medical remains committed to developing and manufacturing products for our top-tier medical devices partners that improve healthcare outcomes for clinicians and their patients worldwide. Our employees strive to exceed our customers' expectations each and every day. They take great pride and ownership of our business, with which I am proud to be associated."
"We are very excited to promote Mark to CEO of Tegra Medical. As the Chief Operating Officer of Tegra, Mark has demonstrated tremendous leadership, commitment and execution. I am confident that Mark will provide complete continuity for our customers and employees and that he will continue to lead Tegra's efforts to deliver operational excellence for our customers," said David Belluck, Chairman of the Board of Tegra Medical and General Partner of Riverside Partners.
About Tegra Medical:
Tegra Medical is focused exclusively on the medical device industry, providing precision machining, molding, assembly and contract manufacturing services. Tegra uses a wide range of manufacturing technologies to produce complex components and finished devices used in cutting-edge procedures for the leading OEM's. Tegra has 200,000 sq. ft. of modern manufacturing space in four locations (including international) and is FDA and ISO 13485:2003 registered. The company combines a broad spectrum of capabilities with a can-do culture to deliver exceptional solutions, speed and service. Tegra Medical has provided premium quality contract manufacturing and assembly services for the medical device industry for over 20 years. Our markets include:
- Orthopaedics – including arthroscopy, spine, interventional spine, trauma, and joint and dental reconstruction
- Minimally-invasive surgery – including breast biopsy, laparoscopy, endoscopy, soft tissue repair, cardiovascular, gynecology, and interventional spine
- Interventional therapies – including radiology, cardiology, neurology, peripheral vascular therapy, and electrophysiology
- Other medical areas – such as diabetes, drug delivery, opthalmology and dental that require a high level of precision.
About Riverside Partners:
Founded in 1989, Riverside Partners is a middle market private equity firm currently investing Riverside Partners Fund V, L.P. The fund focuses on growth-oriented companies primarily in the healthcare and technology industries. Riverside Partners is particularly experienced at partnering with founders, owners and management teams and it brings substantial domain expertise and operating experience to its portfolio companies. Today, Riverside Partners manages $1 billion of equity capital and seeks to make investments in companies with revenues between $20 and $200 million and with $5-$25 million of EBITDA. For more information, please visit www.riversidepartners.com.
SOURCE Tegra Medical